Loan & DebtApr 7, 2026, 06:06 AM
Opus Genetics Enters $155 Million Senior Secured Note Purchase Agreement
AI Summary
Opus Genetics entered into a senior secured note purchase agreement for up to $155 million with OPCM SA LLC and other purchasers. The agreement includes an initial $105 million committed, with tranches dependent on milestones including FDA application acceptance and approval for OPGx-LCA5, providing significant funding for the company's operations and development programs.
Key Highlights
- Opus Genetics secures up to $155 million in senior secured notes.
- Initial commitment of $105 million with remaining $50 million uncommitted.
- Tranches are tied to FDA milestones for OPGx-LCA5, including application acceptance and approval.